Monika Hakerud
Overview
Explore the profile of Monika Hakerud including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
339
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Otterhaug T, Janetzki S, Welters M, Hakerud M, Nedberg A, Edwards V, et al.
Front Immunol
. 2021 Jan;
11:576756.
PMID: 33488576
Background And Aims: Photochemical internalization (PCI) is a technology for inducing release of endocytosed antigens into the cell cytosol a light-induced process. Preclinical experiments have shown that PCI improves MHC...
2.
Haug M, Brede G, Hakerud M, Nedberg A, Gederaas O, Flo T, et al.
Front Immunol
. 2018 Apr;
9:650.
PMID: 29670624
Effective priming and activation of tumor-specific CD8+ cytotoxic T lymphocytes (CTLs) is crucial for realizing the potential of therapeutic cancer vaccination. This requires cytosolic antigens that feed into the MHC...
3.
Endosome Targeting meso-Tetraphenylchlorin-Chitosan Nanoconjugates for Photochemical Internalization
Gaware V, Hakerud M, Juzeniene A, Hogset A, Berg K, Masson M
Biomacromolecules
. 2017 Mar;
18(4):1108-1126.
PMID: 28245649
Four amphiphilic covalently linked meso-tetraphenylchlorin-chitosan nanoconjugates were synthesized and evaluated for use in photochemical internalization (PCI) in vitro and in vivo. The synthetic protocol for the preparation of two different...
4.
Hjalmsdottir A, Buhler C, Vonwil V, Roveri M, Hakerud M, Wackerle-Men Y, et al.
Mol Pharm
. 2015 Dec;
13(2):320-9.
PMID: 26704885
One of the greatest pharmaceutical challenges in vaccinology is the delivery of antigens to the cytosol of antigen-presenting cells (APCs) in order to allow for the stimulation of major histocompatibility...
5.
Bruno C, Waeckerle-Men Y, Hakerud M, Kundig T, Gander B, Johansen P
J Immunol
. 2015 May;
195(1):166-73.
PMID: 26019274
The generation of CTLs is crucial in the immunological fight against cancer and many infectious diseases. To achieve this, vaccine Ags need to be targeted to the cytosol of dendritic...
6.
Hakerud M, Selbo P, Waeckerle-Men Y, Contassot E, Dziunycz P, Kundig T, et al.
J Control Release
. 2014 Dec;
198:10-7.
PMID: 25482339
Cancer vaccines aim to induce CD8 T cells infiltrating the tumour. For protein-based vaccines, the main biological barrier to overcome is the default MHC class-II-pathway, with activation of CD4 T...
7.
Hakerud M, Waeckerle-Men Y, Selbo P, Kundig T, Hogset A, Johansen P
J Control Release
. 2013 Nov;
174:143-50.
PMID: 24280261
The protection or treatment of several immunological disorders is dependent on the antigen-specific and cytotoxic CD8 T cells. However, vaccines aimed at stimulating CD8 T-cell responses are typically ineffective because...
8.
Waeckerle-Men Y, Mauracher A, Hakerud M, Mohanan D, Kundig T, Hogset A, et al.
Eur J Pharm Biopharm
. 2013 Mar;
85(1):34-41.
PMID: 23461859
Tumour chemotherapy with drugs is typically associated with severe systemic and local side effects for which reason immunotherapy represents a safer alternative. However, vaccination often fails to generate the required...
9.
Gaware V, Hakerud M, Leosson K, Jonsdottir S, Hogset A, Berg K, et al.
J Med Chem
. 2013 Jan;
56(3):807-19.
PMID: 23281854
Water-soluble amphiphilic chitosan nanocarriers tethered with the photosensitizer meso-tetraphenylporphyrin were synthesized in a seven-step procedure, starting from 3,6-di-O-tert-butyldimethylsilyl-chitosan and 5-(p-aminophenyl)-10,15,20-triphenylporphyrin. The lipophilic photosensitizer could be introduced in a quantitative and...
10.
Malysz J, Anderson D, Gronlien J, Ji J, Bunnelle W, Hakerud M, et al.
J Pharmacol Exp Ther
. 2010 May;
334(3):863-74.
PMID: 20504915
Enhancement of alpha7 nicotinic acetylcholine receptor (nAChR) activity is considered a therapeutic approach for ameliorating cognitive deficits present in Alzheimer's disease and schizophrenia. In this study, we describe the in...